US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5082936A
(en)
|
1984-11-28 |
1992-01-21 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US5028703A
(en)
|
1988-03-11 |
1991-07-02 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US4992540A
(en)
|
1984-11-28 |
1991-02-12 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US4810646A
(en)
|
1984-11-28 |
1989-03-07 |
Massachusetts Institute Of Technology |
Glucan compositions and process for preparation thereof
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
DE3529497A1
(de)
|
1985-08-17 |
1987-02-26 |
Boehringer Mannheim Gmbh |
N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
ES2103276T3
(es)
|
1989-09-08 |
1997-09-16 |
Alpha Beta Technology |
Composicion para la activacion del sistema inmunitario.
|
EP0490995A1
(en)
|
1989-09-08 |
1992-06-24 |
Alpha Beta Technology |
Method for producing soluble glucans
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
WO1991013080A1
(en)
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
CA2040374C
(en)
|
1990-07-06 |
1998-06-16 |
Gunnar Rorstad |
Process for enhancing the resistance of aquatic animals to disease
|
ES2259177T3
(es)
|
1990-08-13 |
2006-09-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotidos modificados en el azucar que detectan y modulan la expresion genica.
|
JP3256539B2
(ja)
|
1990-08-28 |
2002-02-12 |
エポック・ファーマシューティカルズ・インコーポレイテッド |
連結分子を介する3’―尾分子付オリゴヌクレオチドの固体支持体合成
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
GB9022560D0
(en)
|
1990-10-17 |
1990-11-28 |
G B Biotechnology Limited |
Processing of waste
|
US5419966A
(en)
|
1991-06-10 |
1995-05-30 |
Microprobe Corporation |
Solid support for synthesis of 3'-tailed oligonucleotides
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
US5652359A
(en)
|
1993-12-02 |
1997-07-29 |
Epoch Pharmaceuticals, Inc. |
Oligonucleotides containing n-methyl thiolated bases having antiviral activity
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
AU5979296A
(en)
|
1995-06-07 |
1996-12-30 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
AUPN398295A0
(en)
|
1995-07-05 |
1995-07-27 |
Carlton And United Breweries Limited |
Chemical compounds and processes for their production
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
JP4135318B2
(ja)
|
1997-12-15 |
2008-08-20 |
アステラス製薬株式会社 |
新規なピリミジン−5−カルボキサミド誘導体
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
US8017742B2
(en)
|
1999-11-10 |
2011-09-13 |
Japan Science And Technology Agency |
Gene carrier
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
CA2416442C
(en)
|
2000-07-24 |
2010-06-08 |
Krenitsky Pharmaceuticals, Inc. |
Substituted 5-alkynyl pyrimidines having neurotrophic activity
|
AU2001279796A1
(en)
|
2000-08-03 |
2002-02-18 |
Abac R & D Gmbh |
Isolation of glucan particles and uses thereof
|
US6476003B1
(en)
|
2000-11-06 |
2002-11-05 |
Immusonic, Inc. |
Method for preparing small particle size glucan in a dry material
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
US7786094B2
(en)
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
WO2004033620A2
(en)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of rna interference
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
US20050026286A1
(en)
|
2003-03-05 |
2005-02-03 |
Jen-Tsan Chi |
Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
|
WO2004094595A2
(en)
|
2003-04-17 |
2004-11-04 |
Alnylam Pharmaceuticals Inc. |
MODIFIED iRNA AGENTS
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
EP2567693B1
(en)
|
2003-07-16 |
2015-10-21 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering RNA
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
PL2338332T3
(pl)
|
2004-05-20 |
2014-07-31 |
Eden Research Plc |
Cząsteczka glukanu kapilarnego lub cząsteczka ściany komórkowej zamykająca składnik terpenowy
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
ATE526991T1
(de)
|
2005-10-24 |
2011-10-15 |
Univ Massachusetts |
Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
|
EP1981543A1
(en)
|
2006-01-23 |
2008-10-22 |
Abbott Laboratories |
Chemically modified polycation polymer for sirna delivery
|
PT2712618T
(pt)
|
2006-06-23 |
2017-01-26 |
Engeneic Molecular Delivery Pty Ltd |
Entrega localizada de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamíferos por meio de células bacterianas exterminadas intactas
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
EP2064223B1
(en)
|
2006-09-22 |
2013-04-24 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US20090043367A1
(en)
|
2007-08-09 |
2009-02-12 |
Yitzhak Zilberman |
Apparatus and methods for removing an electronic implant from a body
|
CA2713379A1
(en)
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
WO2010033246A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
AU2011252799B2
(en)
*
|
2010-05-14 |
2015-05-14 |
Cold Spring Harbor Laboratory |
Compositions and methods for treating leukemia
|
US9006199B2
(en)
*
|
2011-11-14 |
2015-04-14 |
Silenseed Ltd. |
Methods and compositions for treating prostate cancer
|
WO2014076703A1
(en)
*
|
2012-11-14 |
2014-05-22 |
Silenseed Ltd. |
Methods and compositions for treating cancer
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|